Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
30 Octobre 2024 - 9:30PM
UK Regulatory
Cellectis to Report Third Quarter 2024 Financial Results on
November 4, 2024
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) --
Cellectis (the “Company”) (Euronext Growth:
ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using
its pioneering gene-editing platform to develop life-saving cell
and gene therapies, today announced that it will report financial
results for the third quarter 2024 ending September 30, 2024 on
Monday, November 4, 2024 after the close of the US market.
The publication will be followed by an investor
conference call and webcast on Tuesday, November 5, 2024 at 8:00 AM
ET / 2:00 PM CET. The call will include the Company’s third quarter
results and an update on business activities. Details for the call
are as follows:
Dial in information:
Domestic: +1-800-225-9448
International: +1-203-518-9708
Conference ID: CLLSQ3
Webcast Link:
https://viavid.webcasts.com/starthere.jsp?ei=1688144&tp_key=affca25222
About Cellectis
Cellectis is a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop
life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with 25
years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
To find out more, visit our website:
www.cellectis.com
Follow Cellectis on social networks @cellectis
on LinkedIn and X (formerly Twitter)
TALEN® is a registered trademark owned by
Cellectis.
For further information on Cellectis, please
contact:
Media
contacts:
Pascalyne Wilson, Director, Communications, +33
(0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the
CEO, +33 (0)7 76 77 46 93
Investor Relations
contact:
Arthur Stril, Interim Chief Financial Officer,
+1 (347) 809 5980, investors@cellectis.com
- 20241030_Q3 2024 earnings call announcement_ENGLISH
Cellectis Nom Eo 05 (EU:ALCLS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024